68 results about "Brain lesions" patented technology

Featured is a method and device for increasing learning and effects of training. Such methods include locating a pair of electrodes on a head of a person in relation to a specific area of the brain, applying a desired DC current to the electrodes at a level sufficient to stimulate the brain tissue; and controlling the DC current application so the current is applied to the specific brain area at least one of before, during or after such a learning or training event. In this way, application of the DC current to the brain area improves a subject's ability to acquire one of motor skills or knowledge of the learning or training event or the ability to retain the motor skills or knowledge of the learning or training event. The person to which the electrodes are attached can be healthy or a patient after brain lesions.

A medical imaging probe (102) for contact with an imaging subject includes an indicium placement apparatus for, while the probe is in contact, selectively performing an instance of marking the subject so as to record a position of the probe. The device may further include a feed-back module for determining whether an orientation, with respect to a the mark, that currently exists for a medical imaging probe of the device meets a criterion of proximity to a predetermined orientation. Responsive to the determination that the criterion is met, a quantitative evaluation may be made automatically and without need for user intervention, vis live imaging via the probe, of a lesion that was, prior to the determination, specifically identified for the evaluation. Change, such as growth (116), in the lesion, like a brain lesion, may thereby be tracked over consistent sequential imaging acquisitions, such as through ultrasound.

The invention belongs to the field of pharmaceuticals and relates to a cascade brain-targeting drug delivery system and the application thereof. The cascade brain-targeting drug delivery system comprises a first-stage target functional molecule, a second-stage target functional molecule and a drug carrier. The cascade target drug delivery system can identify the blood-brain barrier through the first-stage target functional molecule and identify a brain lesion through the second-stage target functional molecule, so as to achieve the accurate targeting purpose, and can also accurately transfer imaging molecules or drugs to the brain lesion, so as to achieve good imaging and therapeutic effects. The cascade brain-targeting drug delivery system can be applied to prepare formulations for treatment or diagnosis of brain diseases (such as brain tumors) and nervous system diseases.

A marking catheter made out of a flexible material and having a closed distal end and an open proximal end is provided. The marking catheter is sized and shaped to fit over the probe of a frameless stereotaxy system. One or more marking catheters may be positioned using the frameless stereotaxy system to define accurately an area identified in pre-operative imaging. For example, a plurality of marking catheters may be used to define physically the margins of a brain lesion. The brain lesion may then be removed to expose the positioned catheters, thereby assuring complete and effective lesion removal. The flexible catheters will move with any brain-shift occurring during lesion removal, thereby to maintain an accurate indication of the lesion margin.

Compositions and methods for enhancing vascular integrity in animals are disclosed. The compositions and methods, which utilize long chain polyunsaturated fatty acids and nitric oxide releasing compounds are also effective for reducing ischemia-induced brain injury in an animal.

In a human or animal organ or other region of interest, specific objects, such as liver metastases and brain lesions, serve as indicators, or biomarkers, of disease. In a three-dimensional image of the organ, the biomarkers are identified and quantified both before and after a surgical implant is implanted, and their reaction to the surgical implant is observed. Statistical segmentation techniques are used to identify the biomarker in a first image and to carry the identification over to the remaining images.

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

The invention discloses a brain-like disease treatment tissue model based on a cell three-dimensional printing technology and a preparation method and application thereof. The preparation method comprises the steps of mixing primary nerve cells extracted from the affected part of the brain lesion with a hydrogel material and a cross-linking agent to obtain a printing biological ink; performing printing molding on the priting biological ink based on the mechanical characteristics of the layer structure and elastic modulus of the natural cerebral cortex by adopting the biological three-dimensional printing technology and then performing tissue culture to obtain the brain-like disease treatment tissue model based on the cell three-dimensional printing technology. Based on the morphological and mechanical properties of the natural brain, the in vitro brain-like model is constructed by the biological three-dimensional printing technology. An extracellular matrix suitable for nerve cell growth and survival can be constructed by controlling the elastic modulus of the extracellular matrix, and the primary cells that are not prone to survive can be adopted for printing. The model has the function of screening drugs in different biological and chemical properties and is a drug screening model with the blood-brain-barrier similar effects.

The invention relates to the field of positioning brain lesion areas, and specifically provides a system for positioning a brain lesion area. The system comprises a flexible conduit for intervening in brain tissues, and the flexible conduit is provided with an ultrasonic probe and/or an optical detector. The ultrasonic probe emits supersonic signals to brain tissues and receives supersonic signals reflected by the brain tissues, and the optical detector emits optical signals to the brain tissues and receives optical signals reflected by the brain tissues. The system further comprises a processor which identifies structure and blood volume change of the brain tissues according to the supersonic signals reflected by the brain tissues and received by the ultrasonic probe, and/or identifies structure and blood volume change of the brain tissues according to the optical signals reflected and/or scattered by the brain tissues and received by the optical detector to position the brain lesion area. Only minimally invasive drilling in the brain of a patient is required to accurately position the brain lesion area through supersonic signals, thereby substantially reducing clinic risk and damage to the body of the patient.

The invention relates to a brain lesion area volume obtaining method and device based on deep learning, computer equipment and a storage medium. The method comprises the following steps: acquiring CTperfusion imaging data related to the brain, wherein the CT perfusion imaging data are a plurality of CT perfusion images arranged according to a scanning time sequence; calculating according to the CT perfusion imaging data to obtain corresponding multi-channel image data; inputting multi-channel image data into the trained deep learning network, and obtaining a plurality of corresponding segmented images, wherein each segmented image comprises an infarction core region and an ischemia semi-dark region; and constructing a brain model in a three-dimensional form based on the plurality of segmented images, and performing calculation according to the brain model to obtain volumes of the infarction core region and the ischemia semi-dark region. By adopting the method, the accuracy and the calculation speed can be improved.

The invention belongs to the technical field of image processing and application, and particularly relates to a brain lesion image spatial distribution feature classification and identification methodbased on magnetic resonance imaging. The method mainly comprises the steps of focus segmentation, individual image registration, space standardization, standard space template individualization, focus space distribution feature extraction, feature screening, modeling and the like. The core is in that an analysis method of a brain lesion image spatial distribution feature set is constructed by analyzing various features of lesions in an individual space and a standard space, and feature screening and modeling are carried out by using machine learning on the basis of the analysis method. The method can be used for classifying and identifying brain lesion images of different brain diseases or brain states caused by different antibodies, different genes and the like by using brain magnetic resonance images, and effective guidance is provided for clinic and scientific research.

The present disclosure relates to a brain disease diagnosis service apparatus including at least: a receiving unit for receiving an image of a subject to be diagnosed; a preprocessing unit for estimating a transformation matrix in order to align a predetermined standard image with the image received by the receiving unit, and for applying the estimated transformation matrix to a predetermined standard brain region map, thereby generating an individual brain region map for the subject to be diagnosed; a feature point extracting unit for calculating a ratio occupied by brain lesions for each brain region in the individual brain region map, generated by the preprocessing unit, of the subject to be diagnosed, thereby extracting feature points; and a disability type determining unit for determining a disability type on the basis of the ratio of the brain lesions, calculated by the feature point extracting unit, for each brain region.

Methods, apparatuses, systems, and implementations for creating 3-dimensional (3D) representations exhibiting geometric and surface characteristics of brain lesions are disclosed. 2D and/or 3D MRI images of the brain may be acquired. Brain lesions and other abnormalities may be identified and isolated with each lesion serving as a region of interest (ROI). Saved ROI may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D brain lesion images may be used to create 3D printed models of the isolated brain lesions using 3D printing technology. Analysis of the 3D brain lesion images and the 3D printed brain lesion models may enable a more efficient and accurate way of determining brain lesion etiologies.

A composition that has an activity of ameliorating reduced higher brain functions resulting from organic brain lesions, said composition comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid as well as docosahexaenoic acid and/or a compound having docosahexaenoic acid as a constituent fatty acid.

A surgeon utilizes a brain scan image to locate a brain lesion and to plan the operation to treat it. Distance measurements representing the location of the lesion are derived from various views of a brain scan image. In the operating room, he transfers these distance measurements onto the patient's cranium in a “warped” or curvilinear Cartesian coordinate system defined by intersecting orthogonal lines extending along the surface of the patient's cranium. As a result, the lesion is localized and the surgeon may establish the appropriate location and orientation of a bone flap to be used to access the lesion.

The invention relates to the field of biotechnology, and discloses a monoclonal antibody against a neurofilament light polypeptide (NEFL). The antibody is secreted by a hybridoma cell line OTI11F6 with a preservation number of CGMCC No.18189. The immunogen of the antibody is a NEFL 1-360aa polypeptide expressed by prokaryotic cells. An amino acid sequence of a light polypeptide (VL) of the antibody is as shown in SEQ ID No.1, and an amino acid sequence of a heavy polypeptide (VH) of the antibody is as shown in SEQ ID No.2. The VL of the antibody comprises three antigenic determinants: CDR1, CDR2, and CDR3, amino acid sequences of the three antigenic determinants are respectively as shown in SEQ ID No.3-5, the VH region of the antibody comprises three antigenic determinants: CDR1, CDR2, andCDR3, and amino acid sequences of the three antigenic determinants are respectively as shown in SEQ ID No.6-8. The antibody OTI11F6 can be applied to preparation of various immunoassay kits of NEFL,such as preparation of double-antibody sandwich enzyme-linked immunosorbent assay kits or chemiluminescence assay kits, and assistant diagnoses for brain injury and chronic brain lesions are provided.

The present invention relates to a medical instrument for automatically detecting affected regions in an examination area of a subject comprising: a memory containing machine executable instructions; and a processor for controlling the medical instrument, wherein execution of the machine executable instructions causes the processor to control the instrument to: obtain a first anatomical image of the examination area and a first image of fibers of the examination area, wherein a first parameter and a second parameter describe characteristics of the first anatomical image and the first image of fibers respectively; segment the first anatomical image into a plurality of segments indicating respective tissues and/or structures in the examination area; identify first lesions in the segmented first anatomical image; use values of the first and/or second parameters for determining seed points in the identified first lesions for a tracking algorithm for tracking first fibers in the first image of fibers.

The invention provides an imaging method and a device thereof and a nuclear magnetic system. The imaging method is applied to the nuclear magnetic system with an ADC image acquisition function. The method comprises the following steps of: obtaining a multi-layer apparent dispersion coefficient ADC image of a scanned brain, determining at least one first connected region from an infarct core candidate region of each layer of ADC image, determining an area in the ADC image, which is symmetrical to the first connected area in structure, as a second connected area, according to the first relativeADCs of the pixel points in the first connected area and the second relative ADCs of the pixel points in the second connected area, determining a target infarcted core region and a target ischemic penumbra from the first connected region and the second connected region, and marking the target infarcted core region and the target ischemic penumbra are ed in the ADC image. The method provided by theinvention has the advantage of high accuracy of a lesion region detection result, and can accurately mark a brain lesion region on the ADC image.

The invention relates to an infantile cerebral palsy acupuncture point heat treatment plaster, which is a plaster for external use for treating infantile cerebral palsy. The infantile cerebral palsy acupuncture point heat treatment plaster consists of folium artemisiae argyi, lumbricus, Chinese angelica, kudzu root, nux vomica, storax, borneol, cinnamon, Kanlisha and magnetic treatment sheets, has the function of improving the brain tissue blood circulation and the brain tissue function, recovering brain lesion blood and oxygen supply, activating the damaged dormant brain tissue cells and vibrating and treating the palsy, has good treatment effect and quick return during the treatment of the infantile cerebral palsy, can achieve the effect of addressing both symptoms and root causes and the goal of not easily relapsing after recovery.

The present invention relates to a pharmaceutical composition which includes a biocompatible polymer and a eukaryotic cell to be used as a drug for the prevention and/or treatment of tissue lesions ofthe central nervous system caused by cerebral vascular ischaemia. The present invention also relates to a pharmaceutical kit which includes a biocompatible polymer and a eukaryotic cell for the prevention and/or treatment of tissue lesions of the central nervous system caused by cerebral vascular ischaemia. The present invention can be used in particular in the human and veterinary pharmaceuticalfields.